Allogene Therapeutics (NASDAQ:ALLO) Rating Reiterated by HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its target price decreased by JPMorgan Chase & Co. from $9.00 to $8.00 in a research note published on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. A number of other equities research analysts also recently weighed in on the […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at Zacks Research lifted their Q1 2024 earnings per share estimates for Allogene Therapeutics in a report issued on Tuesday, February 6th. Zacks Research analyst S. Ganoria now expects that the company will earn ($0.48) per share for the quarter, up from their prior forecast […]
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price target lowered by HC Wainwright from $12.00 to $10.00 in a report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also issued reports about the company. Guggenheim lowered Allogene Therapeutics from a buy rating to a […]
Guggenheim lowered shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) from a buy rating to a neutral rating in a report published on Friday, MarketBeat reports. Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. cut their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set […]